nodes	percent_of_prediction	percent_of_DWPC	metapath
Rifaximin—CYP3A4—Methylprednisolone—ankylosing spondylitis	0.175	0.248	CbGbCtD
Rifaximin—CYP3A4—Triamcinolone—ankylosing spondylitis	0.133	0.188	CbGbCtD
Rifaximin—CYP3A4—Betamethasone—ankylosing spondylitis	0.114	0.161	CbGbCtD
Rifaximin—CYP3A4—Prednisolone—ankylosing spondylitis	0.112	0.159	CbGbCtD
Rifaximin—CYP3A4—Prednisone—ankylosing spondylitis	0.106	0.15	CbGbCtD
Rifaximin—CYP3A4—Dexamethasone—ankylosing spondylitis	0.0662	0.0938	CbGbCtD
Rifaximin—Abdominal discomfort—Methotrexate—ankylosing spondylitis	0.000929	0.00316	CcSEcCtD
Rifaximin—Haemorrhage—Prednisone—ankylosing spondylitis	0.000928	0.00316	CcSEcCtD
Rifaximin—Malaise—Triamcinolone—ankylosing spondylitis	0.000922	0.00314	CcSEcCtD
Rifaximin—Malaise—Methylprednisolone—ankylosing spondylitis	0.00092	0.00313	CcSEcCtD
Rifaximin—Vertigo—Triamcinolone—ankylosing spondylitis	0.000919	0.00313	CcSEcCtD
Rifaximin—Syncope—Triamcinolone—ankylosing spondylitis	0.000917	0.00312	CcSEcCtD
Rifaximin—Vertigo—Methylprednisolone—ankylosing spondylitis	0.000917	0.00312	CcSEcCtD
Rifaximin—Syncope—Methylprednisolone—ankylosing spondylitis	0.000915	0.00312	CcSEcCtD
Rifaximin—Anaphylactic shock—Prednisolone—ankylosing spondylitis	0.000907	0.00309	CcSEcCtD
Rifaximin—Neutropenia—Methotrexate—ankylosing spondylitis	0.000906	0.00309	CcSEcCtD
Rifaximin—Dysuria—Methotrexate—ankylosing spondylitis	0.000906	0.00309	CcSEcCtD
Rifaximin—Upper respiratory tract infection—Methotrexate—ankylosing spondylitis	0.000901	0.00307	CcSEcCtD
Rifaximin—Loss of consciousness—Triamcinolone—ankylosing spondylitis	0.000899	0.00306	CcSEcCtD
Rifaximin—Loss of consciousness—Methylprednisolone—ankylosing spondylitis	0.000897	0.00305	CcSEcCtD
Rifaximin—Shock—Prednisolone—ankylosing spondylitis	0.000893	0.00304	CcSEcCtD
Rifaximin—Cough—Triamcinolone—ankylosing spondylitis	0.000892	0.00304	CcSEcCtD
Rifaximin—Photosensitivity reaction—Methotrexate—ankylosing spondylitis	0.000885	0.00301	CcSEcCtD
Rifaximin—Hyperhidrosis—Prednisolone—ankylosing spondylitis	0.000877	0.00299	CcSEcCtD
Rifaximin—Myalgia—Triamcinolone—ankylosing spondylitis	0.000871	0.00296	CcSEcCtD
Rifaximin—Pneumonia—Methotrexate—ankylosing spondylitis	0.000869	0.00296	CcSEcCtD
Rifaximin—Myalgia—Methylprednisolone—ankylosing spondylitis	0.000869	0.00296	CcSEcCtD
Rifaximin—Arthralgia—Methylprednisolone—ankylosing spondylitis	0.000869	0.00296	CcSEcCtD
Rifaximin—Infestation—Methotrexate—ankylosing spondylitis	0.000864	0.00294	CcSEcCtD
Rifaximin—Infestation NOS—Methotrexate—ankylosing spondylitis	0.000864	0.00294	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ankylosing spondylitis	0.000863	0.00294	CcSEcCtD
Rifaximin—Depression—Methotrexate—ankylosing spondylitis	0.000862	0.00293	CcSEcCtD
Rifaximin—Flushing—Prednisone—ankylosing spondylitis	0.000861	0.00293	CcSEcCtD
Rifaximin—Ill-defined disorder—Dexamethasone—ankylosing spondylitis	0.000861	0.00293	CcSEcCtD
Rifaximin—Ill-defined disorder—Betamethasone—ankylosing spondylitis	0.000861	0.00293	CcSEcCtD
Rifaximin—Discomfort—Triamcinolone—ankylosing spondylitis	0.00086	0.00293	CcSEcCtD
Rifaximin—Discomfort—Methylprednisolone—ankylosing spondylitis	0.000858	0.00292	CcSEcCtD
Rifaximin—Dry mouth—Triamcinolone—ankylosing spondylitis	0.000851	0.0029	CcSEcCtD
Rifaximin—Angioedema—Betamethasone—ankylosing spondylitis	0.000848	0.00289	CcSEcCtD
Rifaximin—Angioedema—Dexamethasone—ankylosing spondylitis	0.000848	0.00289	CcSEcCtD
Rifaximin—Angiopathy—Prednisone—ankylosing spondylitis	0.000842	0.00287	CcSEcCtD
Rifaximin—Confusional state—Methylprednisolone—ankylosing spondylitis	0.00084	0.00286	CcSEcCtD
Rifaximin—Malaise—Dexamethasone—ankylosing spondylitis	0.000837	0.00285	CcSEcCtD
Rifaximin—Malaise—Betamethasone—ankylosing spondylitis	0.000837	0.00285	CcSEcCtD
Rifaximin—Anaphylactic shock—Triamcinolone—ankylosing spondylitis	0.000834	0.00284	CcSEcCtD
Rifaximin—Vertigo—Betamethasone—ankylosing spondylitis	0.000834	0.00284	CcSEcCtD
Rifaximin—Vertigo—Dexamethasone—ankylosing spondylitis	0.000834	0.00284	CcSEcCtD
Rifaximin—Anaphylactic shock—Methylprednisolone—ankylosing spondylitis	0.000833	0.00284	CcSEcCtD
Rifaximin—Syncope—Betamethasone—ankylosing spondylitis	0.000832	0.00283	CcSEcCtD
Rifaximin—Syncope—Dexamethasone—ankylosing spondylitis	0.000832	0.00283	CcSEcCtD
Rifaximin—Infection—Triamcinolone—ankylosing spondylitis	0.000829	0.00282	CcSEcCtD
Rifaximin—Infection—Methylprednisolone—ankylosing spondylitis	0.000827	0.00282	CcSEcCtD
Rifaximin—Haematuria—Methotrexate—ankylosing spondylitis	0.000824	0.00281	CcSEcCtD
Rifaximin—Shock—Triamcinolone—ankylosing spondylitis	0.000821	0.0028	CcSEcCtD
Rifaximin—Insomnia—Prednisolone—ankylosing spondylitis	0.000821	0.00279	CcSEcCtD
Rifaximin—Shock—Methylprednisolone—ankylosing spondylitis	0.000819	0.00279	CcSEcCtD
Rifaximin—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.000817	0.00278	CcSEcCtD
Rifaximin—Loss of consciousness—Dexamethasone—ankylosing spondylitis	0.000815	0.00278	CcSEcCtD
Rifaximin—Loss of consciousness—Betamethasone—ankylosing spondylitis	0.000815	0.00278	CcSEcCtD
Rifaximin—Epistaxis—Methotrexate—ankylosing spondylitis	0.000815	0.00277	CcSEcCtD
Rifaximin—Mental disorder—Prednisone—ankylosing spondylitis	0.000813	0.00277	CcSEcCtD
Rifaximin—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.000809	0.00275	CcSEcCtD
Rifaximin—Malnutrition—Prednisone—ankylosing spondylitis	0.000808	0.00275	CcSEcCtD
Rifaximin—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	0.000807	0.00275	CcSEcCtD
Rifaximin—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	0.000805	0.00274	CcSEcCtD
Rifaximin—Myalgia—Dexamethasone—ankylosing spondylitis	0.00079	0.00269	CcSEcCtD
Rifaximin—Myalgia—Betamethasone—ankylosing spondylitis	0.00079	0.00269	CcSEcCtD
Rifaximin—Discomfort—Dexamethasone—ankylosing spondylitis	0.00078	0.00266	CcSEcCtD
Rifaximin—Discomfort—Betamethasone—ankylosing spondylitis	0.00078	0.00266	CcSEcCtD
Rifaximin—Haemoglobin—Methotrexate—ankylosing spondylitis	0.00078	0.00265	CcSEcCtD
Rifaximin—Hypotension—Methylprednisolone—ankylosing spondylitis	0.000778	0.00265	CcSEcCtD
Rifaximin—Pain—Prednisolone—ankylosing spondylitis	0.000776	0.00264	CcSEcCtD
Rifaximin—Haemorrhage—Methotrexate—ankylosing spondylitis	0.000776	0.00264	CcSEcCtD
Rifaximin—Pharyngitis—Methotrexate—ankylosing spondylitis	0.00077	0.00262	CcSEcCtD
Rifaximin—Urinary tract disorder—Methotrexate—ankylosing spondylitis	0.000766	0.00261	CcSEcCtD
Rifaximin—Urethral disorder—Methotrexate—ankylosing spondylitis	0.00076	0.00259	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	0.00076	0.00259	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	0.000759	0.00258	CcSEcCtD
Rifaximin—Anaphylactic shock—Betamethasone—ankylosing spondylitis	0.000757	0.00258	CcSEcCtD
Rifaximin—Anaphylactic shock—Dexamethasone—ankylosing spondylitis	0.000757	0.00258	CcSEcCtD
Rifaximin—Insomnia—Triamcinolone—ankylosing spondylitis	0.000755	0.00257	CcSEcCtD
Rifaximin—Insomnia—Methylprednisolone—ankylosing spondylitis	0.000753	0.00256	CcSEcCtD
Rifaximin—Infection—Betamethasone—ankylosing spondylitis	0.000752	0.00256	CcSEcCtD
Rifaximin—Infection—Dexamethasone—ankylosing spondylitis	0.000752	0.00256	CcSEcCtD
Rifaximin—Ill-defined disorder—Prednisone—ankylosing spondylitis	0.00075	0.00255	CcSEcCtD
Rifaximin—Feeling abnormal—Prednisolone—ankylosing spondylitis	0.000748	0.00255	CcSEcCtD
Rifaximin—Anaemia—Prednisone—ankylosing spondylitis	0.000747	0.00254	CcSEcCtD
Rifaximin—Shock—Dexamethasone—ankylosing spondylitis	0.000745	0.00254	CcSEcCtD
Rifaximin—Shock—Betamethasone—ankylosing spondylitis	0.000745	0.00254	CcSEcCtD
Rifaximin—Dyspnoea—Triamcinolone—ankylosing spondylitis	0.000744	0.00253	CcSEcCtD
Rifaximin—Nervous system disorder—Betamethasone—ankylosing spondylitis	0.000743	0.00253	CcSEcCtD
Rifaximin—Nervous system disorder—Dexamethasone—ankylosing spondylitis	0.000743	0.00253	CcSEcCtD
Rifaximin—Angioedema—Prednisone—ankylosing spondylitis	0.000738	0.00251	CcSEcCtD
Rifaximin—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	0.000732	0.00249	CcSEcCtD
Rifaximin—Hyperhidrosis—Betamethasone—ankylosing spondylitis	0.000732	0.00249	CcSEcCtD
Rifaximin—Malaise—Prednisone—ankylosing spondylitis	0.000729	0.00248	CcSEcCtD
Rifaximin—Vertigo—Prednisone—ankylosing spondylitis	0.000726	0.00247	CcSEcCtD
Rifaximin—Syncope—Prednisone—ankylosing spondylitis	0.000725	0.00247	CcSEcCtD
Rifaximin—Tinnitus—Methotrexate—ankylosing spondylitis	0.000723	0.00246	CcSEcCtD
Rifaximin—Anorexia—Dexamethasone—ankylosing spondylitis	0.000722	0.00246	CcSEcCtD
Rifaximin—Anorexia—Betamethasone—ankylosing spondylitis	0.000722	0.00246	CcSEcCtD
Rifaximin—Urticaria—Prednisolone—ankylosing spondylitis	0.000721	0.00245	CcSEcCtD
Rifaximin—Fatigue—Triamcinolone—ankylosing spondylitis	0.000719	0.00245	CcSEcCtD
Rifaximin—Fatigue—Methylprednisolone—ankylosing spondylitis	0.000718	0.00244	CcSEcCtD
Rifaximin—Pain—Triamcinolone—ankylosing spondylitis	0.000714	0.00243	CcSEcCtD
Rifaximin—Loss of consciousness—Prednisone—ankylosing spondylitis	0.00071	0.00242	CcSEcCtD
Rifaximin—Hypotension—Betamethasone—ankylosing spondylitis	0.000708	0.00241	CcSEcCtD
Rifaximin—Hypotension—Dexamethasone—ankylosing spondylitis	0.000708	0.00241	CcSEcCtD
Rifaximin—Angiopathy—Methotrexate—ankylosing spondylitis	0.000704	0.0024	CcSEcCtD
Rifaximin—Mediastinal disorder—Methotrexate—ankylosing spondylitis	0.000699	0.00238	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	0.00069	0.00235	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	0.00069	0.00235	CcSEcCtD
Rifaximin—Arthralgia—Prednisone—ankylosing spondylitis	0.000688	0.00234	CcSEcCtD
Rifaximin—Myalgia—Prednisone—ankylosing spondylitis	0.000688	0.00234	CcSEcCtD
Rifaximin—Feeling abnormal—Triamcinolone—ankylosing spondylitis	0.000688	0.00234	CcSEcCtD
Rifaximin—Feeling abnormal—Methylprednisolone—ankylosing spondylitis	0.000686	0.00234	CcSEcCtD
Rifaximin—Insomnia—Dexamethasone—ankylosing spondylitis	0.000685	0.00233	CcSEcCtD
Rifaximin—Insomnia—Betamethasone—ankylosing spondylitis	0.000685	0.00233	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.000683	0.00233	CcSEcCtD
Rifaximin—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	0.000681	0.00232	CcSEcCtD
Rifaximin—Discomfort—Prednisone—ankylosing spondylitis	0.00068	0.00231	CcSEcCtD
Rifaximin—Mental disorder—Methotrexate—ankylosing spondylitis	0.00068	0.00231	CcSEcCtD
Rifaximin—Malnutrition—Methotrexate—ankylosing spondylitis	0.000675	0.0023	CcSEcCtD
Rifaximin—Hypersensitivity—Prednisolone—ankylosing spondylitis	0.000669	0.00228	CcSEcCtD
Rifaximin—Urticaria—Triamcinolone—ankylosing spondylitis	0.000663	0.00226	CcSEcCtD
Rifaximin—Urticaria—Methylprednisolone—ankylosing spondylitis	0.000661	0.00225	CcSEcCtD
Rifaximin—Body temperature increased—Triamcinolone—ankylosing spondylitis	0.00066	0.00225	CcSEcCtD
Rifaximin—Anaphylactic shock—Prednisone—ankylosing spondylitis	0.000659	0.00225	CcSEcCtD
Rifaximin—Abdominal pain—Methylprednisolone—ankylosing spondylitis	0.000658	0.00224	CcSEcCtD
Rifaximin—Decreased appetite—Betamethasone—ankylosing spondylitis	0.000658	0.00224	CcSEcCtD
Rifaximin—Decreased appetite—Dexamethasone—ankylosing spondylitis	0.000658	0.00224	CcSEcCtD
Rifaximin—Infection—Prednisone—ankylosing spondylitis	0.000655	0.00223	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.000654	0.00223	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.000654	0.00223	CcSEcCtD
Rifaximin—Back pain—Methotrexate—ankylosing spondylitis	0.000653	0.00222	CcSEcCtD
Rifaximin—Fatigue—Dexamethasone—ankylosing spondylitis	0.000653	0.00222	CcSEcCtD
Rifaximin—Fatigue—Betamethasone—ankylosing spondylitis	0.000653	0.00222	CcSEcCtD
Rifaximin—Shock—Prednisone—ankylosing spondylitis	0.000649	0.00221	CcSEcCtD
Rifaximin—Pain—Dexamethasone—ankylosing spondylitis	0.000647	0.0022	CcSEcCtD
Rifaximin—Pain—Betamethasone—ankylosing spondylitis	0.000647	0.0022	CcSEcCtD
Rifaximin—Nervous system disorder—Prednisone—ankylosing spondylitis	0.000647	0.0022	CcSEcCtD
Rifaximin—Skin disorder—Prednisone—ankylosing spondylitis	0.00064	0.00218	CcSEcCtD
Rifaximin—Hyperhidrosis—Prednisone—ankylosing spondylitis	0.000637	0.00217	CcSEcCtD
Rifaximin—Anorexia—Prednisone—ankylosing spondylitis	0.000629	0.00214	CcSEcCtD
Rifaximin—Ill-defined disorder—Methotrexate—ankylosing spondylitis	0.000627	0.00213	CcSEcCtD
Rifaximin—Anaemia—Methotrexate—ankylosing spondylitis	0.000624	0.00212	CcSEcCtD
Rifaximin—Feeling abnormal—Dexamethasone—ankylosing spondylitis	0.000624	0.00212	CcSEcCtD
Rifaximin—Feeling abnormal—Betamethasone—ankylosing spondylitis	0.000624	0.00212	CcSEcCtD
Rifaximin—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	0.000619	0.00211	CcSEcCtD
Rifaximin—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	0.000619	0.00211	CcSEcCtD
Rifaximin—Hypersensitivity—Triamcinolone—ankylosing spondylitis	0.000615	0.00209	CcSEcCtD
Rifaximin—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	0.000613	0.00209	CcSEcCtD
Rifaximin—Malaise—Methotrexate—ankylosing spondylitis	0.000609	0.00207	CcSEcCtD
Rifaximin—Vertigo—Methotrexate—ankylosing spondylitis	0.000607	0.00207	CcSEcCtD
Rifaximin—Urticaria—Betamethasone—ankylosing spondylitis	0.000602	0.00205	CcSEcCtD
Rifaximin—Urticaria—Dexamethasone—ankylosing spondylitis	0.000602	0.00205	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	0.000601	0.00205	CcSEcCtD
Rifaximin—Dizziness—Prednisolone—ankylosing spondylitis	0.0006	0.00204	CcSEcCtD
Rifaximin—Asthenia—Triamcinolone—ankylosing spondylitis	0.000599	0.00204	CcSEcCtD
Rifaximin—Body temperature increased—Dexamethasone—ankylosing spondylitis	0.000599	0.00204	CcSEcCtD
Rifaximin—Abdominal pain—Dexamethasone—ankylosing spondylitis	0.000599	0.00204	CcSEcCtD
Rifaximin—Body temperature increased—Betamethasone—ankylosing spondylitis	0.000599	0.00204	CcSEcCtD
Rifaximin—Abdominal pain—Betamethasone—ankylosing spondylitis	0.000599	0.00204	CcSEcCtD
Rifaximin—Asthenia—Methylprednisolone—ankylosing spondylitis	0.000597	0.00203	CcSEcCtD
Rifaximin—Insomnia—Prednisone—ankylosing spondylitis	0.000596	0.00203	CcSEcCtD
Rifaximin—Pruritus—Triamcinolone—ankylosing spondylitis	0.00059	0.00201	CcSEcCtD
Rifaximin—Cough—Methotrexate—ankylosing spondylitis	0.000589	0.00201	CcSEcCtD
Rifaximin—Pruritus—Methylprednisolone—ankylosing spondylitis	0.000589	0.00201	CcSEcCtD
Rifaximin—Chest pain—Methotrexate—ankylosing spondylitis	0.000575	0.00196	CcSEcCtD
Rifaximin—Arthralgia—Methotrexate—ankylosing spondylitis	0.000575	0.00196	CcSEcCtD
Rifaximin—Myalgia—Methotrexate—ankylosing spondylitis	0.000575	0.00196	CcSEcCtD
Rifaximin—Decreased appetite—Prednisone—ankylosing spondylitis	0.000573	0.00195	CcSEcCtD
Rifaximin—Rash—Prednisolone—ankylosing spondylitis	0.000572	0.00195	CcSEcCtD
Rifaximin—Dermatitis—Prednisolone—ankylosing spondylitis	0.000572	0.00195	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	0.000571	0.00194	CcSEcCtD
Rifaximin—Diarrhoea—Methylprednisolone—ankylosing spondylitis	0.00057	0.00194	CcSEcCtD
Rifaximin—Fatigue—Prednisone—ankylosing spondylitis	0.000569	0.00194	CcSEcCtD
Rifaximin—Headache—Prednisolone—ankylosing spondylitis	0.000568	0.00194	CcSEcCtD
Rifaximin—Discomfort—Methotrexate—ankylosing spondylitis	0.000568	0.00193	CcSEcCtD
Rifaximin—Constipation—Prednisone—ankylosing spondylitis	0.000564	0.00192	CcSEcCtD
Rifaximin—Confusional state—Methotrexate—ankylosing spondylitis	0.000556	0.00189	CcSEcCtD
Rifaximin—Dizziness—Triamcinolone—ankylosing spondylitis	0.000552	0.00188	CcSEcCtD
Rifaximin—Anaphylactic shock—Methotrexate—ankylosing spondylitis	0.000551	0.00188	CcSEcCtD
Rifaximin—Dizziness—Methylprednisolone—ankylosing spondylitis	0.000551	0.00187	CcSEcCtD
Rifaximin—Infection—Methotrexate—ankylosing spondylitis	0.000547	0.00186	CcSEcCtD
Rifaximin—Feeling abnormal—Prednisone—ankylosing spondylitis	0.000543	0.00185	CcSEcCtD
Rifaximin—Asthenia—Betamethasone—ankylosing spondylitis	0.000543	0.00185	CcSEcCtD
Rifaximin—Asthenia—Dexamethasone—ankylosing spondylitis	0.000543	0.00185	CcSEcCtD
Rifaximin—Nervous system disorder—Methotrexate—ankylosing spondylitis	0.00054	0.00184	CcSEcCtD
Rifaximin—Gastrointestinal pain—Prednisone—ankylosing spondylitis	0.000539	0.00184	CcSEcCtD
Rifaximin—Nausea—Prednisolone—ankylosing spondylitis	0.000539	0.00184	CcSEcCtD
Rifaximin—Pruritus—Betamethasone—ankylosing spondylitis	0.000536	0.00182	CcSEcCtD
Rifaximin—Pruritus—Dexamethasone—ankylosing spondylitis	0.000536	0.00182	CcSEcCtD
Rifaximin—Skin disorder—Methotrexate—ankylosing spondylitis	0.000535	0.00182	CcSEcCtD
Rifaximin—Hyperhidrosis—Methotrexate—ankylosing spondylitis	0.000533	0.00181	CcSEcCtD
Rifaximin—Vomiting—Triamcinolone—ankylosing spondylitis	0.000531	0.00181	CcSEcCtD
Rifaximin—Vomiting—Methylprednisolone—ankylosing spondylitis	0.000529	0.0018	CcSEcCtD
Rifaximin—Rash—Triamcinolone—ankylosing spondylitis	0.000526	0.00179	CcSEcCtD
Rifaximin—Dermatitis—Triamcinolone—ankylosing spondylitis	0.000526	0.00179	CcSEcCtD
Rifaximin—Anorexia—Methotrexate—ankylosing spondylitis	0.000525	0.00179	CcSEcCtD
Rifaximin—Rash—Methylprednisolone—ankylosing spondylitis	0.000525	0.00179	CcSEcCtD
Rifaximin—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.000525	0.00179	CcSEcCtD
Rifaximin—Urticaria—Prednisone—ankylosing spondylitis	0.000524	0.00178	CcSEcCtD
Rifaximin—Headache—Triamcinolone—ankylosing spondylitis	0.000523	0.00178	CcSEcCtD
Rifaximin—Headache—Methylprednisolone—ankylosing spondylitis	0.000522	0.00178	CcSEcCtD
Rifaximin—Body temperature increased—Prednisone—ankylosing spondylitis	0.000521	0.00177	CcSEcCtD
Rifaximin—Abdominal pain—Prednisone—ankylosing spondylitis	0.000521	0.00177	CcSEcCtD
Rifaximin—Diarrhoea—Betamethasone—ankylosing spondylitis	0.000518	0.00176	CcSEcCtD
Rifaximin—Diarrhoea—Dexamethasone—ankylosing spondylitis	0.000518	0.00176	CcSEcCtD
Rifaximin—Hypotension—Methotrexate—ankylosing spondylitis	0.000515	0.00175	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	0.000502	0.00171	CcSEcCtD
Rifaximin—Dizziness—Betamethasone—ankylosing spondylitis	0.000501	0.0017	CcSEcCtD
Rifaximin—Dizziness—Dexamethasone—ankylosing spondylitis	0.000501	0.0017	CcSEcCtD
Rifaximin—Insomnia—Methotrexate—ankylosing spondylitis	0.000498	0.0017	CcSEcCtD
Rifaximin—Nausea—Triamcinolone—ankylosing spondylitis	0.000496	0.00169	CcSEcCtD
Rifaximin—Nausea—Methylprednisolone—ankylosing spondylitis	0.000495	0.00168	CcSEcCtD
Rifaximin—Dyspnoea—Methotrexate—ankylosing spondylitis	0.000491	0.00167	CcSEcCtD
Rifaximin—Hypersensitivity—Prednisone—ankylosing spondylitis	0.000486	0.00165	CcSEcCtD
Rifaximin—Vomiting—Betamethasone—ankylosing spondylitis	0.000481	0.00164	CcSEcCtD
Rifaximin—Vomiting—Dexamethasone—ankylosing spondylitis	0.000481	0.00164	CcSEcCtD
Rifaximin—Decreased appetite—Methotrexate—ankylosing spondylitis	0.000479	0.00163	CcSEcCtD
Rifaximin—Rash—Dexamethasone—ankylosing spondylitis	0.000477	0.00163	CcSEcCtD
Rifaximin—Rash—Betamethasone—ankylosing spondylitis	0.000477	0.00163	CcSEcCtD
Rifaximin—Dermatitis—Betamethasone—ankylosing spondylitis	0.000477	0.00162	CcSEcCtD
Rifaximin—Dermatitis—Dexamethasone—ankylosing spondylitis	0.000477	0.00162	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	0.000476	0.00162	CcSEcCtD
Rifaximin—Fatigue—Methotrexate—ankylosing spondylitis	0.000475	0.00162	CcSEcCtD
Rifaximin—Headache—Betamethasone—ankylosing spondylitis	0.000474	0.00162	CcSEcCtD
Rifaximin—Headache—Dexamethasone—ankylosing spondylitis	0.000474	0.00162	CcSEcCtD
Rifaximin—Asthenia—Prednisone—ankylosing spondylitis	0.000473	0.00161	CcSEcCtD
Rifaximin—Pain—Methotrexate—ankylosing spondylitis	0.000471	0.0016	CcSEcCtD
Rifaximin—Pruritus—Prednisone—ankylosing spondylitis	0.000467	0.00159	CcSEcCtD
Rifaximin—Feeling abnormal—Methotrexate—ankylosing spondylitis	0.000454	0.00155	CcSEcCtD
Rifaximin—Diarrhoea—Prednisone—ankylosing spondylitis	0.000451	0.00154	CcSEcCtD
Rifaximin—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	0.000451	0.00153	CcSEcCtD
Rifaximin—Nausea—Betamethasone—ankylosing spondylitis	0.00045	0.00153	CcSEcCtD
Rifaximin—Nausea—Dexamethasone—ankylosing spondylitis	0.00045	0.00153	CcSEcCtD
Rifaximin—Urticaria—Methotrexate—ankylosing spondylitis	0.000438	0.00149	CcSEcCtD
Rifaximin—Dizziness—Prednisone—ankylosing spondylitis	0.000436	0.00148	CcSEcCtD
Rifaximin—Abdominal pain—Methotrexate—ankylosing spondylitis	0.000436	0.00148	CcSEcCtD
Rifaximin—Body temperature increased—Methotrexate—ankylosing spondylitis	0.000436	0.00148	CcSEcCtD
Rifaximin—Vomiting—Prednisone—ankylosing spondylitis	0.000419	0.00143	CcSEcCtD
Rifaximin—Rash—Prednisone—ankylosing spondylitis	0.000416	0.00142	CcSEcCtD
Rifaximin—Dermatitis—Prednisone—ankylosing spondylitis	0.000415	0.00141	CcSEcCtD
Rifaximin—Headache—Prednisone—ankylosing spondylitis	0.000413	0.00141	CcSEcCtD
Rifaximin—Hypersensitivity—Methotrexate—ankylosing spondylitis	0.000406	0.00138	CcSEcCtD
Rifaximin—Asthenia—Methotrexate—ankylosing spondylitis	0.000395	0.00135	CcSEcCtD
Rifaximin—Nausea—Prednisone—ankylosing spondylitis	0.000392	0.00133	CcSEcCtD
Rifaximin—Pruritus—Methotrexate—ankylosing spondylitis	0.00039	0.00133	CcSEcCtD
Rifaximin—Diarrhoea—Methotrexate—ankylosing spondylitis	0.000377	0.00128	CcSEcCtD
Rifaximin—Dizziness—Methotrexate—ankylosing spondylitis	0.000364	0.00124	CcSEcCtD
Rifaximin—Vomiting—Methotrexate—ankylosing spondylitis	0.00035	0.00119	CcSEcCtD
Rifaximin—Rash—Methotrexate—ankylosing spondylitis	0.000347	0.00118	CcSEcCtD
Rifaximin—Dermatitis—Methotrexate—ankylosing spondylitis	0.000347	0.00118	CcSEcCtD
Rifaximin—Headache—Methotrexate—ankylosing spondylitis	0.000345	0.00118	CcSEcCtD
Rifaximin—Nausea—Methotrexate—ankylosing spondylitis	0.000327	0.00111	CcSEcCtD
